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Aim: To determine the protective effects of L-carnitine on cardiovascular changes that may occur in rabbits treated with
adrenocorticotropic hormone (ACTH) and dexamethasone (DEX).
Materials and methods: Rabbits of equal weight were divided into 7 groups with 6 animals in each. Blood samples were collected from
all groups on days 1, 7, and 14, and blood pressure values and ECG monitoring were recorded. Nitric oxide (NO), creatine kinase MB
(CK-MB), and troponin I (TnI) levels were determined in blood samples. Heart rate, QT, and corrected QT (QTc) values were calculated
from ECG records.
Results: The QT and QTc times were prolonged significantly (P < 0.001) in the ACTH-treated groups compared to the control group,
and L-carnitine had no protective effect. Moreover, CK-MB (P < 0.05) and TnI (P < 0.001) levels were higher in the ACTH-treated
groups than they were in the control group.
Conclusion: Application of ACTH results in prolongation of QT and QTc intervals and increases in CK-MB and TnI levels, which are
indicators of heart muscle damage.
Key words: Nitric oxide, QT, CK-MB, troponin, ACTH, carnitine

1. Introduction
Acute and chronic stresses increase the risk of
atherosclerosis and coronary artery diseases (1). Cortisol
and similar hormones released from the adrenal cortex
are known as natural glucocorticoids (GCs) (2). Natural
and synthetic GCs are known to cause increases in blood
pressure by decreasing mRNA stabilization of endothelial
nitric oxide synthase (eNOS) and slowing down its gene
transcription. Nitric oxide (NO) plays a major role in
the regulation of blood pressure. An increase in blood
pressure when treated with glucocorticoids is associated
with a decrease in NO production (3,4).
Many factors, mainly elevated blood pressure, may
result in myocardial disorders. Electrocardiography (ECG)
and biochemical markers are employed to detect defects in
the myocardium accurately and immediately. Troponin I
and creatine kinase MB (CK-MB) are examples of these
biochemical markers (5,6).
L-carnitine is used to treat patients with ischemic heart
disease, congestive heart incapability, and atherosclerotic
peripheral artery disease (7). Gomez-Ameros et al.

(8) showed that with its antioxidant nature propionylL-carnitine protects the liver and heart in the case of
oxidative stress associated hypertension.
This study was performed to investigate the protective
effect of L-carnitine and L-arginine on cardiovascular
changes in rabbits injected with ACTH and dexamethasone
(DEX).
2. Materials and methods
2.1. Animals and experimental design
This study was conducted on 42 New Zealand rabbits 10–
14 months old of both sexes and between 2.7 and 3.1 kg
body weight. The rabbits were fed a special rabbit pellet
diet ad libitum. The animals were kept in cages with the
room temperature set to 21 °C and with 12 h light/12 h
dark schedule. The experimental protocol was approved by
the Laboratory Animal Care and Use Committee of Kafkas
University.
The animals were divided into 7 groups with 6 rabbits in
each. The control group received 0.5 mL of isotonic solution
per rabbit via subcutaneous injection twice daily for 14
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days. A 0.5-mL dose of ACTH (Synacthen Depot, 1 mg/
mL, Ciba-Geigy, Novartis Pharma AG, Basel, Switzerland)
was given per rabbit via subcutaneous injection twice daily
for 14 days. A single dose of DEX (Calvasone, 2 mg/mL;
50 mL, Sanovel Pharma, İstanbul, Turkey) was given at a
dose of 0.2 mL/per rabbit via subcutaneous injection daily
for 14 days. L-carnitine solution (Carnitine, Oral, 30%,
20 mL; Sigma-Tau, Rome, Italy) was given orally for 14
days. L-arginine (Cat no: 11010, Fluka, SIGMA GmBH,
Germany), which was dissolved in isotonic solution, was
applied orally for 14 days as a single dose.
The experimental design and the treatments were as
follows:
Group 1 (CG); n = 6, isotonic solution, 1 mL per rabbit
per day (subcutaneously),
Group 2 (ACTH); n = 6, ACTH, 1 mg per rabbit per
day (subcutaneously),
Group 3 (ACTH-LC); n = 6, ACTH, 1 mg per rabbit
per day (subcutaneously) + L-carnitine, 200 mg/kg/day
(orally),
Group 4 (ACTH-LA); n = 6, ACTH, 1 mg per rabbit
per day (subcutaneously) + L-arginine, 200 mg/kg/day
(orally),
Group 5 (DEX); n = 6, DEX, 400 µg per rabbit per day
(subcutaneously),
Group 6 (DEX-LC); n = 6, DEX, 400 µg per rabbit
per day (subcutaneously) + L-carnitine, 200 mg/kg/day
(orally),
Group 7 (DEX-LA); n = 6, DEX, 400 µg per rabbit
per day (subcutaneously) + L-arginine, 200 mg/kg/day
(orally).
2.2. Electrocardiography recording
The electrocardiographic procedure was performed as
reported by Uzun et al. (9). ECG records were taken
for all rabbits before the experiment (baseline) and on
days 1, 7, and 14 of the experiment by direct writing
electrocardiograph (Poly-Spectrum 12 channel ECGSystem, Poly-Spectru-8, Neurosoft, Ivanovo, Russia). ECG
recordings were loaded onto a computer and analyzed
manually. No sedatives or anesthetics were given to the
animals before or during ECG recording. ECG recordings
standardized at 1 mV = 20 mm, with chart speed of 50
mm/s with filter and Leads I, II, III, aVR, aVL, and aVF
were obtained. The QT interval was corrected for heart rate
(HR) with the formula (QTcF = QT/(RR)1/3) as described
by Fridericia et al. (10).
2.3. Measurements of blood pressure
For the purpose of blood pressure measurements, the
sensitive part of the device was tied to the brachial artery,
which is located above the articulatio cubiti, in the foreleg
of the rabbit. The systolic blood pressure (SBP), mean
blood pressure (MBP), and diastolic blood pressure
(DBP) values were recorded by the oscillometric method

(Memoprint S+B, medVET GmBH, Germany) on days 1,
7, and 14 (11).
2.4. Collection of blood samples
Blood samples were collected from the V. auricularis of
the animals in all groups 2 h after the injections on days
1, 7, and 14 of the experiment. Plasmas were separated
by centrifugation at 3000 rpm for 10 min. Plasma
samples were stored at –20 °C until the analysis following
deproteinization.
2.5. Analysis of NO
Plasma NO levels were measured according to Miranda et
al. (12). After the plasma samples were deproteinized with
10% zinc sulfate, the samples were centrifuged at 1400
rpm for 10 min. Then total NO concentrations (via NO
metabolites: nitrate and nitrite) were determined with the
acidic Griess reaction by colorimetric method.
2.6. Analysis of CK-MB and troponin I
CK-MB analyses were performed using spectrophotometric
measurements (Cat. no. TR90231, IBL, Turkey). Tn I levels
were determined by ELISA kit (Cat. no. EIA-2952, IBL,
Turkey).
2.7. Statistical analysis of data
Data were analyzed with MINITAB statistical software
(Minitab Inc., Pennsylvania, USA). Differences between
the groups at the same sampling time and differences
between the sampling times within the groups for QT, QTc,
RR, SBP, MBP, DBP, HR, NO, CK-MB, and TnI values were
determined with one-way ANOVA. Pearson’s correlation
was used to determine the relationships between the
investigated parameters. All of the data are expressed as
means ± SEMs. The level of significance was set at P < 0.05.
3. Results
In NO levels, the only significant difference was observed
on day 1 in the DEX-LC group. NO levels on each sampling
day with statistical significance are indicated in Table 1 (P
< 0.05).
There was no significant difference between the groups
in terms of CK-MB activity on day 1 of the experiment.
CK-MB values were higher in all ACTH applied groups.
The highest value of CK-MB was 581 ± 248 U/L on day
7 when ACTH was applied and 289 ± 58 U/L on day 14
when ACTH-LA was applied. It was also found that the
difference between ACTH and DEX-LA on day 7 and the
difference between ACTH-LA and DEX-LA on day 14
were significant (P < 0.05; Table 1).
No significant difference was observed between days
1 and 7 in TnI levels between the groups. Nevertheless,
an increase in the level of TnI was detected in the ACTH
applied group in comparison to the other groups. The level
of TnI on day 14 in the ACTH-LC group was significantly
different compared to that in the CG, DEX, DEX-LC, and
DEX-LA groups (P < 0.001; Table 1).
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Table 1. The NO, CK-MB, and troponin I levels in the control and treatment groups.
Parameters

NO

*

CK-MB*

Tn I**

Day

CG
(n = 6)

ACTH
(n = 6)

ACTH-LC
(n = 6)

ACTH-LA
(n = 6)

DEX
(n = 6)

DEX-LC
(n = 6)

DEX-LA
(n = 6)

1

39 ± 2a

37 ± 2a

38 ± 4a

46 ± 4ab

46 ± 3ab

55 ± 4b

42 ± 4ab

7

34 ± 3

33 ± 2

35 ± 2

32 ± 1

33 ± 2

36 ± 3

39 ± 4

14

48 ± 3

39 ± 1

47 ± 3

42 ± 5

47 ± 3

43 ± 2

43 ± 3

1

113 ± 28

215 ± 56

250 ± 62

325 ± 123

147 ± 48

65 ± 10

149 ± 47

7

106 ± 28ab

581 ± 248a

313 ± 97ab

412 ± 116ab

152 ± 40ab

105 ± 45ab

76 ± 20b

14

145 ± 30

159 ± 31

190 ± 32

289 ± 58

148 ± 31

152 ± 76

34 ± 40b

ab

ab

ab

a

ab

ab

1

0.036 ± 0.02

0.178 ± 0.07

0.125 ± 0.06

0.076 ± 0.02

0.036 ± 0.02

0.035 ± 0.02

0.045 ± 0.02

7

0.021 ± 0.01

0.414 ± 0.20

0.242 ± 0.06

0.279 ± 0.10

0.376 ± 0.31

0.050 ± 0.03

0.134 ± 0.07

14

0.017 ± 0.02a 0.132 ± 0.03abc 0.232 ± 0.07b 0.151 ± 0.07abc 0.017 ± 0.02ac 0.013 ± 0.01ac 0.028 ± 0.02ac

*: P < 0.05, **: P < 0.001. The values within the same row with different superscripts differ significantly.

4. Discussion
In the present study, the effects of L-carnitine and L-arginine
on expected cardiovascular changes in rabbits treated
with ACTH and DEX were investigated.
The
most
obvious changes among the investigated parameters were
determined in the QT and QTc intervals. The QT and QTc
times were prolonged significantly in all 3 ACTH applied
groups compared to the CG. The overload of myocardial
cells with positive charged ions during repolarization of
the ventricle results in QT prolongation (13). The increased
afterload can cause ischemia as well as lengthened
QTc intervals by disturbing the electrophysiological
heterogeneity between endocardium and myocardium
(14). It has been reported that the prolongation QT times
can be the cause of deaths due to TdP type ventricular
arrhythmia (15). In addition, prolongations were observed
in QT and QTc times in the groups treated with DEX, but

HR was higher in the ACTH applied group in
comparison to the control and DEX groups and the
difference was significant on some sampling days.
The mean values of pulse in all groups and the level of
significance are presented in Table 2.
In comparison to the control group, QT and QTc times
on days 1, 7, and 14 were significantly prolonged (P <
0.001) in all 3 ACTH applied groups.
The SBP, DBP, and MBP values and the differences
between the groups on days 1, 7, and 14 are shown in
Table 3. A lower systolic blood pressure level was observed
in the ACTH-LA applied group compared to the other
groups, whereas in the DEX applied groups it was highest
on day 14. Moreover, the differences between the ACTHLA (92 ± 4 mmHg), DEX (117 ± 7 mmHg), and DEX-LC
(117 ± 5 mmHg) groups in terms of SBP were statistically
significant (P < 0.05).

Table 2. The heart rate, QT, and QTc values in the control and treatment groups.
Parameters

HR

QT

QTc

Day

CG
(n = 6)

ACTH
(n = 6)

ACTH-LC
(n = 6)

ACTH-LA
(n = 6)

DEX
(n = 6)

DEX-LC
(n = 6)

DEX-LA
(n = 6)

1

238 ± 6ad

257 ± 9b

248 ± 12ab

243 ± 12abd

209 ± 9c

230 ± 9d

240 ± 13ad

7

251 ± 9ab

246 ± 6ad

264 ± 7bc

272 ± 6c

231 ± 13d

251 ± 10ab

245 ± 13ad

14

233 ± 7

265 ± 15

253 ± 11

243 ± 7

234 ± 15

244 ± 13ac

1

133 ± 2a

144 ± 4b

154 ± 9c

153 ± 6c

138 ± 5ab

136 ± 2ab

135 ± 3a

7

133 ± 3

146 ± 3

150 ± 3

150 ± 4

146 ± 3

cd

142 ± 3

138 ± 2d

14

139 ± 1a

155 ± 5b

142 ± 7ad

149 ± 4bc

142 ± 3ad

147 ± 4cd

143 ± 3ac

1

210 ± 4

b

232 ± 5

246 ± 11

243 ± 6

209 ± 8

a

213 ± 1

214 ± 3a

7

213 ± 4ae

234 ± 3b

245 ± 4cd

248 ± 5d

227 ± 4b

228 ± 7b

220 ± 4be

14

218 ± 2

248 ± 5

231 ± 10

240 ± 7

226 ± 4

230 ± 4

227 ± 2e

a

ad

a

a

249 ± 12

abc

bc

bd

b

b

c

ce

bc

b

bc

cd

The values within the same row with different superscripts differ significantly (P < 0.001).
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Table 3. The SBP, DBP, and MBP values in the control and treatment groups.
Parameters

SBP

DBP

MBP

Day

CG
(n = 6)

ACTH
(n = 6)

ACTH-LC
(n = 6)

ACTH-LA
(n = 6)

DEX
(n = 6)

DEX-LC
(n = 6)

DEX-LA
(n = 6)

1

105 ± 5

99 ± 4

103 ± 4

109 ± 6

111 ± 9

123 ± 9

96 ± 4

7

109 ± 5

113 ± 12

99 ± 6

91 ± 2

119 ± 7

124 ± 10

119 ± 5

14

106 ± 6abc

105 ± 8abc

106 ± 3abc

92 ± 4a

117 ± 7b

117 ± 5bc

108 ± 4abc

1

68 ± 4abc

56 ± 3b

59 ± 4abc

63 ± 3abc

61 ± 6abc

76 ± 6ac

57 ± 3b

7

70 ± 5ab

68 ± 8ab

55 ± 5ab

52 ± 3a

79 ± 5b

72 ± 7ab

68 ± 4ab

14

63 ± 4

64 ± 6

59 ± 2

51 ± 6

69 ± 5

67 ± 4

58 ± 5

ac

93 ± 7

71 ± 3b

ab

1

82 ± 4

7

84 ± 5

85 ± 9

14

79 ± 5

79 ± 6

abc
ab

b

72 ± 3

75 ± 4

ab

abc

79 ± 4

abc

79 ± 7

abc

72 ± 5

b

66 ± 2

93 ± 6

91 ± 8

87 ± 4ab

76 ± 2

66 ± 4

86 ± 6

85 ± 4

76 ± 4

ab

a

The values within the same row with different superscripts differ significantly (P < 0.05).

the prolongations in these groups were less than those in
the ACTH treated groups. Increases in TnI and CK-MB
levels, which are indicators of cardiac damage, in the
groups that showed prolonged QT and QTc times may
suggest cardiac damage. Considering the protective effect
of L-carnitine on day 14 on the damage induced by ACTH
and DEX, although the QT and QTc values in the ACTHLC group were higher than those in the CG, the existence
of lower values compared to the ACTH and ACTH-LA
groups can be considered as showing that L-carnitine has
slightly shortened the prolongation of QT and QTc times.
NO, a strong vasodilator that is effective on the
continuation of arterial tone in pulmonary, coronary, and
systemic circulation, is an agent affecting the maintenance
of vascular tone in vessels in humans and other species
(16). Although the impact of endothelium-derived NO on
vessels is well known, its autocrine and paracrine effects
on the heart muscle have been recently highlighted. Low
doses of NO and NO donors, which have different effects
on the heart, lead to a positive inotropic effect, which is
considered to increase basal cardiac function. On the other
hand, when given in high doses, they increase myocyte
relaxation or diastolic function (17). In other studies, it
was claimed that NO influences the autonomic nervous
control of cardiac pulse directly (18), and it facilitates the
ability of the sinoatrial node to create stimulation (19).
In the present study, statistically significant differences
were observed between the groups in terms of NO levels
on day 1 while no differences were determined on days
7 and 14. In the DEX-LC group, determination of an
increase in NO levels on day 1 suggests that L-carnitine,
like L-arginine, leads to an increase in NO production
(20). In addition, no significant correlation between NO
levels and SBP, DBP, MBP, HR, QT, QTc, CK-MB, and TnI
levels was determined in our investigation. Although there

was no correlation between NO levels and blood pressure,
the lower NO levels in the ACTH group compared to
the CG and other groups, and, considering the blood
pressure values on days 7 and 14, the existence of higher
blood pressure in the ACTH group than in the ACTH-LC
and ACTH-LA are consistent with the results of studies
indicating that plasma nitrate/nitrite level is reduced while
blood pressure is increased by ACTH treatment (21,22).
Some researchers (21,23) have reported that increases
in blood pressure due to ACTH through its stimulatory
effects on cortisol and corticosterone secretion are
eliminated by L-arginine application. It has also been
reported that L-arginine decreases blood pressure in
hypertension and reduces the proliferation of vascular
smooth muscle cells by increasing NO production (20).
In a study conducted by Gomez-Amores et al. (8), it was
indicated that propionyl-L-carnitine protects the rat heart
and liver in the case of oxidative stress-related hypertension
because of its antioxidant properties.
In this study, although increases were determined in
SBP, DBP, and MBP values following elevated ACTH levels
and after the application of DEX, the protective effect of
L-arginine was observed on days 7 and 14. This situation
suggests that the efficacy of DEX for increasing the blood
pressure is higher than that of ACTH. Furthermore, when
the L-carnitine was given to the ACTH and DEX treated
groups, a slight but not significant reduction was observed
in blood pressure values on days 7 and 14. The reduced BP
suggests that L-carnitine may also have a protective effect
against the elevated blood pressure resulting from ACTH
and DEX application. However, it can be speculated that
this protective effect is not as effective as that of L-arginine,
because when the groups are compared in terms of SBP
on day 7 the SBP value was 113 ± 12 mmHg in the group
treated with ACTH, whereas in the ACTH-LC group this
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value was 99 ± 6 mmHg and in the ACTH-LA group it
fell to 91 ± 2 mmHg. A similar situation was observed in
the groups treated with DEX; the values of SBP on day 7
in the groups treated with DEX, DEX-LC, and DEX-LA
were 119 ± 7 mmHg, 124 ± 10 mmHg, and 119 ± 5 mmHg,
respectively. In general, a similar trend was observed for
DBP and mean BP values, suggesting that the protective
effects of L-carnitine and L-arginine emerge on days 7
and 14. In addition, the determination of different BP
values in the ACTH and DEX treated groups as well as
the lowering effect of L-arginine not being to the same
extent as L-carnitine may show that both substances have
different efficacies and mode of actions for diminishing
blood pressure.
Troponin, an important marker of cardiac damage,
regulates calcium-mediated actin and myosin interaction
(24). Troponin is in 3 isoforms: TnI, TnT, and TnC.
Troponin I and T are specific markers of heart muscle
damage. TnT increases with kidney and muscle tissue
injuries. TnI is regarded as one of the most specific
indicators of acute myocardial infarction (25). Another
marker of cardiac damage is creatine kinase (CK). This
enzyme has 3 isoforms (26). One of them is CK-MB,
which is specific for heart muscle. The CK level, especially
CK-MB level, increases significantly due to myocardial
damage, and so is regarded as an important indicator of
heart muscle damage (27,28). Many factors, in particular
increase in blood pressure, may cause damage to the heart
muscle.

In the present study, statistically significant increases
were determined on days 7 and 14. CK-MB and TnI levels
are important markers of cardiac damage (5,6). The effect
of ACTH on CK-MB and TnI is more obvious than that of
DEX. In the CG, CK-MB level was 106 ± 28 U/L, whereas
this value reached 581 ± 248 U/L in the ACTH treated
group and in the DEX treated group it was 152 ± 40 U/L
on day 7. On day 14, CK-MB levels in the CG and ACTH
and DEX groups were 145 ± 30 U/L, 159 ± 31 U/L, and
148 ± 31 U/L, respectively. L-carnitine and L-arginine
were used for prophylactic purposes against ACTH and
DEX; they slightly but not significantly decreased CK-MB
activity. CK-MB enzyme is an indicator of cardiac damage
and its level is increased by damage to heart muscle cells.
Therefore, it is accepted as an indicator of myocardial
damage (27,28). The increase in CK-MB level in the group
treated with ACTH suggests that ACTH leads to damage
to the heart muscle cells.
The results of this study showed that ACTH
applications can cause damage to heart muscle cells,
resulting in elevation of cardiac enzymes, but L-carnitine
and L-arginine have no protective effects. However, DEX, a
synthetic glucocorticoid, does not cause severe damage as
ACTH does, and the negative impact of ACTH on the heart
muscle is the result of increased cortisol concentration. In
addition, ACTH and DEX applications may lead to cardiac
arrhythmias due to prolonged QT and QTc intervals, but
there is no correlation between the prolongation of QT
and QTc times and NO and blood pressure.
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